TTRX (Turn Therapeutics) Cash per Share: $0.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $13.49
! 1 Warning Sign
View Full Analysis

What is Turn Therapeutics Cash per Share?

Turn Therapeutics TTRX +5.82% 11 Cash per Share is $0.35 as of Jun. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Turn Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 was $0.35.

Turn Therapeutics  (NAS:TTRX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Turn Therapeutics Cash per Share Related Terms

Turn Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics Cash per Share Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Cash per Share
0.04 0.03 0.17

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.11 0.17 0.38 0.35
TTRX
11GF Score
Turn Therapeutics Inc TTRX
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turn Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Turn Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=5.076/29.45
=0.17

Turn Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=10.289/29.79
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.35 mean?
Turn Therapeutics (TTRX) has a Cash per Share of $0.35 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Turn Therapeutics and its competitors.
Is Turn Therapeutics' Cash per Share too high?
Turn Therapeutics' current Cash per Share is $0.35. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' Cash per Share compare to YDES and BCYC?
Turn Therapeutics' Cash per Share of $0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Turn Therapeutics and its competitors. Turn Therapeutics's current Cash per Share is $0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current Cash per Share of $0.35. The current Cash per Share is $0.35. Turn Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current Cash per Share is $0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.49
Price